Clinical trials: Heart Failure (HF)
Congestive Heart Failure
Heart Failure and Peritoneal Ultrafiltration
The objective of the study is to determine if the addition of peritoneal ultrafiltration to standard therapy in treatment-resistant severe heart failure patients will improve fluid balance and functional capacity such that they…
- Trial name
- NCT00368641
- Testing
- Extraneal
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 12 people
- Sponsor
- Vantive Health LLC
Heart Decompensation
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties…
- Trial name
- NCT00475852
- Testing
- Nesiritide
- Where
- 328 sites in United States, Argentina and 26 more
- Volunteers
- 7,141 people
- Sponsor
- Scios, Inc.
Heart Failure
Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
This is a multicenter, non-interventional, single arm cohort study with prospective collection of primary data via pharmacists in community pharmacies to describe adherence to sacubitril/valsartan in study patients at the end of…
- Trial name
- LOCATE-HF (NCT05870709)
- Testing
- sacubitril/valsartan
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs
This is a randomized double-blind crossover study of the patients with stable heart failure, who are taking a loop diuretic. During the study period, the participants' loop diuretics will be replaced by the equivalent dose of…
- Trial name
- EXTOR-HF (NCT06708611)
- Testing
- torsemide
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Heart Failure, Cardiac Output
Validation of CardioMEMS HF System Cardiac Output Algorithm IDE
The investigation will enroll subjects who have been previously implanted with the CardioMEMS™ Pulmonary Artery Sensor. This clinical investigation is twofold; in the first phase (development phase) data collected will be used to…
- Trial name
- VICTOR (NCT05428384)
- Testing
- MRI/ CardioMEMS comparison
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Sleep Disorder
Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation
The purpose of this study is to assess changes in left ventricular performance using echocardiography as well as ventricular remodelling, changes in sleep and changes in mood, anxiety and cognitive functions occurring as a result…
- Conditions
- Heart Failure, Sleep Disorder, Cheyne Stokes Respiration
- Trial name
- MS (NCT01164592)
- Testing
- adaptive servoventilation (ASV)
- Where
- 94 sites in Australia, Czechia and 6 more
- Volunteers
- 312 people
- Sponsor
- ResMed
Heart Failure, Ventricular Dysfunction
B-Left HF: Biventricular Versus Left Univentricular Pacing With Implantable Cardiac Defibrillator (ICD) Back-Up in Heart Failure Patients
The purpose of this study is to demonstrate that biventricular pacing (BiV) and left univentricular (left ventricular [LV] only) pacing are safe and effective for cardiac resynchronization therapy in heart failure patients…
- Conditions
- Heart Failure, Ventricular Dysfunction, Heart Diseases
- Trial name
- NCT00187213
- Testing
- Cardiac Resynchronization Therapy
- Where
- France
- Sponsor
- Abbott Medical Devices
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
HF Assessment With BNP in the Home: Part II
HABIT-II is a feasibility study aimed at home monitoring of patients with heart failure. B-type natriuretic peptide (BNP) has strong correlations to the severity of heart failure.
- Trial name
- HABIT-II (NCT02351063)
- Testing
- Changes of heart failure medications
- Where
- 13 sites in United States, Ireland and 4 more
- Volunteers
- 1 people
- Sponsor
- Alere San Diego
Atrial Fibrillation, Heart Failure
Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T
The study is designed to collect data of the performance and confirm the safety of the DX (Diagnostic eXtension) functionality in the Lumax 640/470 HF-T in patients with permanent atrial fibrillation and CRT-D indication…
- Trial name
- Pre-CRAFT (NCT01930695)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 18 people
- Sponsor
- Biotronik SE & Co. KG
Heart Failure, Congestive
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before…
- Trial name
- NCT00344513
- Testing
- Beta-blockers including Carvedilol, ACE inhibitors
- Volunteers
- 50,000 people
- Sponsor
- GlaxoSmithKline
Acute Decompensated Heart Failure
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05876078
- Testing
- Doraya catheter
- Where
- 10 sites in Germany, Italy and 3 more
- Volunteers
- 25 people
- Sponsor
- Revamp Medical Ltd.
Heart Failure
Remote Speech Analysis in HF Patients Undergoing Haemodialysis
This is an observational, non-interventional, prospective, single-arm, open study for database establishment for R\&D purposes. The study will be conducted in 1 site in Israel with up to fifty (50) patients.
- Trial name
- NCT03714126
- Testing
- Cordio Medical
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Cordio Medical
Heart Failure
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
First in Human Clinical Investigation of the FIRE1 Device/System to evaluate the feasibility and safety of implanting the FIRE1 system in up to 50 stable HF patients.
- Trial name
- NCT04203576
- Testing
- FIRE1 System
- Where
- 13 sites in Czechia, Georgia and 3 more
- Volunteers
- 50 people
- Sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
Atrioventricular Block, Heart Diseases
Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
- Trial name
- BLOCK HF (NCT00267098)
- Testing
- Cardiac Resynchronization Therapy (CRT)
- Where
- 54 sites in United States, Canada
- Volunteers
- 918 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Congestive Heart Failure
Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure
The purpose of the PRECEDE-HF study is to collect data to compare patients whose heart failure is managed using Cardiac Compass with OptiVol (which is a tool in the device that records information about the heart that doctors can…
- Trial name
- PRECEDE-HF (NCT00510198)
- Testing
- Cardiac Compass with OptiVol Fluid Status Monitoring, Standard of Care alone (clinical assessment)
- Where
- 33 sites in United States
- Volunteers
- 120 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
REDUCE LAP-HF TRIAL
The objective of this clinical study is to evaluate the safety and performance of the IASD System II in the treatment of heart failure patients with elevated left atrial pressure, who remain symptomatic despite appropriate…
- Trial name
- REDUCE LAP-HF (NCT01913613)
- Testing
- IASD
- Where
- 26 sites in Australia, Austria and 9 more
- Volunteers
- 64 people
- Sponsor
- Corvia Medical
Heart Failure
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Trial name
- EVOLUTION-HF (NCT05465213)
- Where
- 8 sites in Portugal
- Volunteers
- 283 people
- Sponsor
- AstraZeneca